9 min read · updated 2026-08-21
Incretin Receptor Agonists: Single, Dual, and Triple Receptor Targeting
What receptor targeting means, how single, dual, and triple agonists differ structurally, and why the naming is confusing.
The receptors involved
Three receptors define this class. The GLP-1 receptor responds to glucagon-like peptide-1, an incretin hormone released from intestinal cells. The GIP receptor responds to glucose-dependent insulinotropic polypeptide, a second incretin. The glucagon receptor responds to glucagon and sits in a related but distinct signalling role. Compounds in this class are described by which of these three they engage — one, two, or all three — and by their relative potency at each, which is a separate question from how many they bind.
Single receptor agonists
A single agonist engages the GLP-1 receptor alone. Long-acting analogues in this group are typically modified in two ways relative to native GLP-1: an aminoisobutyric acid substitution at position 8 confers resistance to DPP-4 cleavage, and a fatty diacid chain promotes albumin binding, both of which extend half-life in published pharmacokinetic characterisation. Laboratory investigation centres on receptor binding affinity and cAMP accumulation in receptor-transfected cell preparations.
Dual receptor agonists
A dual agonist engages both the GIP and GLP-1 receptors. Compounds in this group are typically derived from the GIP sequence and engineered for activity at both receptors, with reported imbalance favouring GIP. The research interest is not simply that two receptors are engaged but that the relative potency at each differs, and that the signalling profile is not the sum of two single agonists. Published work characterises relative receptor potency and beta-arrestin recruitment, which is where the concept of biased agonism enters — a compound may favour one downstream pathway over another at the same receptor.
Triple receptor agonists
A triple agonist engages GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activity is the distinguishing feature and the reason for research attention, since glucagon receptor engagement contributes to energy expenditure endpoints characterised in preclinical models. As with dual agonists, relative potency at each of the three receptors is the parameter under investigation rather than the count of receptors alone.
Why the naming is confusing
Compounds in this class carry several names at once — a research code from development, an international nonproprietary name, and various descriptive labels used by suppliers. Descriptive labels are not standardised across vendors, and some are actively misleading: a numeric label implying a second or third GLP variant does not correspond to any such compound, since GLP-2 is a distinct endogenous peptide unrelated to dual incretin agonism. The reliable identifiers are CAS number, molecular formula, and molecular weight, all of which appear on the compound record and on the certificate. Where a supplier label and a CAS number disagree, the CAS number is the one that means something.
What this means for verification
Identity confirmation for compounds in this class is by LC-MS against the theoretical molecular weight, which differs meaningfully between them — roughly 4114, 4813, and 4731 g/mol for the single, dual, and triple agonists respectively. Because these figures are close, the observed adducts and charge states on a certificate matter more here than in classes where masses are widely separated. A certificate should report the observed masses rather than an unsupported statement that identity was confirmed.
Frequently asked
What is the difference between a single, dual, and triple agonist?
The number of receptors engaged. A single agonist engages the GLP-1 receptor; a dual agonist engages GIP and GLP-1; a triple agonist engages GLP-1, GIP, and glucagon. Relative potency at each receptor differs and is a separate parameter from receptor count.
Is there a compound called GLP-2 in this class?
No. GLP-2 is a distinct endogenous peptide unrelated to dual incretin agonism. Numeric labels implying a second or third GLP variant are supplier descriptions rather than chemical identifiers. Use CAS number and molecular weight to identify a compound.
What is biased agonism?
A compound preferentially activating one downstream signalling pathway over another at the same receptor. In the dual-agonist literature it is characterised through measures such as beta-arrestin recruitment relative to cAMP accumulation.
How is identity confirmed for these compounds?
By LC-MS against theoretical molecular weight. Masses in this class are relatively close together, so the observed adducts and charge states reported on a certificate carry more weight than a bare statement that identity was confirmed.
See the practice, not just the principle
Every lot we release is published in full — assay, method, and measured result — and the record stays online after the lot sells out.
Open the COA library